Advertisement

Advertisement
Gastroesophageal Cancer
Gastrointestinal Cancer
Immunotherapy

FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Previously Treated Patients With HER2-Positive Gastric Cancers

On January 15, the U.S. Food and Drug Administration (FDA) approved fam-trastuzumab deruxtecan-nxki (Enhertu) for adult patients with...

 

Hepatobiliary Cancer

IDH Inhibitor Ivosidenib Improves Overall Survival in Previously Treated Patients With Cholangiocarcinoma: ClarIDHy Trial

Ivosidenib, an inhibitor of isocitrate dehydrogenase 1 (IDH1), improved overall survival by almost 3 months compared with placebo in previously treated...

 

Hematologic Malignancies
Immunotherapy

FDA Grants Accelerated Approval to Daratumumab Plus Hyaluronidase-fihj for Newly Diagnosed Light Chain Amyloidosis

On January 15, the U.S. Food and Drug Administration (FDA) granted accelerated approval to daratumumab plus hyaluronidase-fihj...

 


Advertisement
Colorectal Cancer

Postsurgical Disease Recurrence in Stage I to III Colorectal Cancer May Be Predicted by ctDNA

Patients with stage I to III colorectal cancer and a high risk for disease recurrence may be identified by serial testing of circulating tumor DNA...

 

COVID-19

ASCO Coronavirus Resources

As the coronavirus (COVID-19) continues to spread, ASCO is committed to providing the most current information and resources to its members and the larger oncology...

Advertisement




Supportive Care

Jing Li, MD, PhD, on Brain Metastases: Stereotactic Radiosurgery vs Whole-Brain Radiation Therapy

Solid Tumors
Hematologic Malignancies
COVID-19

Immune Response to COVID-19 Reduced in Patients With Hematologic Malignancies vs Solid Tumors

Patients with hematologic malignancies varied in their immune response to COVID-19, and some struggled to clear the infection, according to new research published by Abdul-Jawad in Cancer Cell. In contrast, most patients with solid tumors—even those with advanced cancer—were shown to be able to...

Advertisement

Impact of Genes on Total Number and Type of Nevi

A study by Duffy et al in the Journal of Investigative Dermatology reported on specific gene variations affecting the number and types of moles on the body and their role in causing skin cancer.  “The goal was to investigate the genetic underpinnings of different mole classes, or...

Breast Cancer

Chirag Shah, MD, on Assessing DCIS Recurrence Risk

Breast Cancer

Palbociclib Plus Endocrine Therapy vs Capecitabine for Patients With HR-Positive, HER2-Negative Breast Cancer: The PEARL Trial

Although patients with hormone receptor (HR)-positive, HER2-negative, aromatase inhibitor–resistant metastatic breast cancer maintained quality of life for a longer time following treatment with palbociclib plus either exemestane or fulvestrant than capecitabine, those receiving chemotherapy...

Breast Cancer
Pain Management

New Study Examines Patterns of Opioid Use Among Patients With Metastatic Breast Cancer

Some patients with metastatic breast cancer are taking smaller doses of opioid prescriptions over decreased amounts of time, according to results published by Shen et al in Scientific Reports. Researchers said that the results indicate that clinicians may be more aware of the negative impacts of...

Gemcitabine/Eribulin in Cisplatin-Ineligible Metastatic Urothelial Carcinoma

In the final analysis from a phase II California Cancer Consortium trial (NCI-9653) reported in the Journal of Clinical Oncology, Sadeghi et al found the combination of gemcitabine and eribulin showed activity in cisplatin-ineligible patients with metastatic urothelial carcinoma. Study Details...

Gastrointestinal Cancer

Rutika Mehta, MD, MPH, on Gastric Cancer: Adjuvant Chemotherapy With S-1 and Docetaxel

Hematologic Malignancies
Symptom Management

Addition of Sitagliptin to Tacrolimus/Sirolimus Prophylaxis for Acute Graft-vs-Host Disease

In a phase II trial reported in The New England Journal of Medicine, Farag et al found that the addition of the dipeptidyl peptidase 4 (DPP-4; CD26) inhibitor sitagliptin to tacrolimus and sirolimus prophylaxis resulted in a low rate of acute graft-vs-host disease among patients with hematologic...

Advertisement

Deintensified Chemoradiotherapy for HPV-Associated Oropharyngeal Squamous Cell Carcinoma

In a phase II trial reported in the Journal of Clinical Oncology, Chera et al found that deintensified chemoradiotherapy produced favorable outcomes in human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma. Study Details In the multicenter trial, 114 patients were recruited...